Fosphenytoin Sodium Injection, USP, 100 mg PE per 2 mL (50 mg PE per mL), 2 mL Single Dose Vial, ...
FDA Drug Recall #D-1437-2012 — Class II — April 13, 2012
Recall Summary
| Recall Number | D-1437-2012 |
| Classification | Class II — Moderate risk |
| Date Initiated | April 13, 2012 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | West-ward Pharmaceutical Corp. |
| Location | Eatontown, NJ |
| Product Type | Drugs |
| Quantity | a) 308,275 vials; b) 2,008,850 vials |
Product Description
Fosphenytoin Sodium Injection, USP, 100 mg PE per 2 mL (50 mg PE per mL), 2 mL Single Dose Vial, packaged in 25-count x 2 mL Single Dose Vials per carton, Rx only, Mfd. By: Hikma Farmaceutica (Portugal), S.A.; Dist. By: West-Ward Pharmaceutical Corp., Eatontown, NJ 07724 USA under the labels a) NOVAPLUS (NDC 0143-9704-25), b) West-Ward (NDC 0143-9788-25).
Reason for Recall
Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stability samples and retain samples.
Distribution Pattern
All lots were distributed throughout the US.
Lot / Code Information
Lot #s: a) 113153.1, 113154.1, 113155.1, Exp 05/13; 113248.1, Exp 07/13; b) 103196.1, 103197.1, 103197.2, 103198.1, Exp 07/12; 103317.1, 103318.1, 103319.1, 103345.1, 103345.2, Exp 11/12; 103346.1, 103347.1, 103348.1, 103349.1, 103350.1, Exp 12/12; 113030.1, 113031.1, 113032.1, 113033.1, 113034.1, 113035.1, 113036.1, Exp 01/13; 113245.1, 113246.1, 113247.1, Exp 07/13
Other Recalls from West-ward Pharmaceutical Corp.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-1139-2015 | Class III | Fentanyl Citrate Inj., USP, CII, 250 mcg/5 mL (... | May 13, 2015 |
| D-0172-2015 | Class II | VERSAPHARM INCORPORATED Ethambutol Hydrochlorid... | Oct 2, 2014 |
| D-1414-2014 | Class II | Isoniazid Tablets, USP, 300 mg, Rx only, packag... | May 20, 2014 |
| D-367-2014 | Class II | Carisoprodol Tablets, USP 350 mg, Rx Only, 1000... | Nov 7, 2013 |
| D-66447-002 | Class II | Irinotecan Hydrochloride Injection, 100 mg/5 mL... | Sep 23, 2013 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.